Navigating global policy shifts: Implications for Europe's pharma landscape

• The value of health in a changing world: Christoph Glaetzer, Chief Global Value and Access Officer at Johnson & Johnson Innovative Medicines, discusses the importance of viewing healthcare as an investment. He highlights the need for fit-for-purpose value assessments and policies that align with scientific advancements to ensure faster adoption of innovative treatments.
• Disruptive global policy trends: Neil Grubert, Independent Global Market Access Consultant, explores the ripple effects of U.S. and Chinese policy developments, including Most-Favored Nation (MFN) pricing, NATO-style drug funding, and China’s advancements in biotechnology, and what they mean for Europe.
• Europe’s policy trajectory: Anja Schiel, Senior Advisor at the Norwegian Medicines Agency (NOMA), examines Europe’s legislative response, including the Health Technology Assessment (HTA) regulation, pharmaceutical legislation revision, Critical Medicines Act, and Biotech Act, and their potential to strengthen Europe’s competitiveness while addressing fragmentation.
• Patient-centric perspectives: Antonella Cardone, CEO of Cancer Patients Europe (CPE), emphasizes the importance of reducing access inequalities, involving patients in decision-making, and ensuring Europe remains competitive to deliver life-saving treatments to all.

Moderated by Casper Paardekooper, Head of Pricing, Policy, and Stakeholder Engagement, Europe, at Cencora, this webinar offers an invaluable opportunity to gain actionable insights into navigating policy challenges, fostering collaboration across stakeholders, and driving innovation while ensuring equitable access for patients.